USFDA inspection at Dr Reddy's FTO-11 facility ends with two Form 483 observations

Regulatory & Legal View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹1180.00

prior close

₹1180.00

announcement price

After-mkt

timing

Nifty 100market+1.2%+0.2% vs market

Pharmaceuticals peers, median of 168sector-0.2%+1.6% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty 100 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.6

15m

-0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+1.2+0.2-0.2+1.6

Next day

+4.2+0.7+3.5-0.3+4.5

+5.1+2.2+3.0-0.4+5.5

+3.1+1.8+1.2-0.7+3.8

+3.3+3.1+0.2-1.2+4.5

+4.5+3.7+0.8-1.0+5.4

+5.5+2.1+3.3-4.2+9.7

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA completed a Pre-Approval Inspection at Dr Reddy's FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh from October 5 to 7, 2026. The company received a Form 483 with two observations and will address them within the stipulated timeline.

Likely market impact

Two observations are relatively minor and manageable; no warning letter or import alert reported. Investors should watch for further USFDA updates or approval delays linked to this site.